Navigation Links
CryoLife Hosts Worldwide Surgical Congress for the Ross Procedure
Date:10/7/2008

Surgical Congress to focus on new patient data supporting the Ross heart reconstruction procedure and the use of SynerGraft processed human heart

valves in the Ross procedure

ATLANTA, Oct. 7 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials, medical device and tissue processing company, announced today that cardiovascular surgeons from around the globe will participate in the Ross Summit 2008, a two-day surgical congress to be held at the Company's corporate headquarters training facility in Kennesaw, Ga. The program, slated for Oct. 10 and 11, has piqued the interest of the worldwide cardiovascular surgical community with approximately 80 cardiovascular surgeons from 11 countries convening to explore new data supporting the patient advantages of the Ross Procedure in cardiac reconstruction surgeries. In addition, the participants will have the opportunity to perfect their surgical techniques related to the procedure and to learn of new, related technologies now available. Mr. Donald N. Ross, FRCS, consultant surgeon, National Heart Hospital, London, and inventor of the procedure, will be the honored guest at the summit.

The Ross Procedure is a type of specialized aortic valve surgery in which the patient's diseased aortic valve is replaced with his or her own pulmonary valve. The pulmonary valve is then replaced with a human cryopreserved pulmonary valve. A new decellurized human pulmonary heart valve, CryoValve(R) SG, processed using CryoLife's SynerGraft(R) technology, was cleared by the FDA in February 2008 for use in cardiac reconstruction procedures including the Ross Procedure.

The Ross Summit's world renowned faculty, directed by William F. Northrup III, M.D., vice president, medical relations and education at CryoLife, Inc., will be led by Professor Sir Magdi Yacoub, FRS, FRCS, Imperial College, London, Heart Science Center.

"In children and young adults, or older, active patients, the Ross Procedure offers several advantages over other traditional aortic valve replacement options. The most important advantage is improved long-term survival," said Dr. Northrup. "However, the procedure requires very specific surgical expertise in order to achieve predictable, long-lasting results. The goal of this Summit is to provide the training necessary from acknowledged experts in the field. By doing so, we hope to expand the number of surgeons who can offer this procedure to their patients."

Additional distinguished cardiovascular surgeons on the Summit faculty include: Prof. Hans Sievers, M.D., FETCS, Klinik fur Herzchirugie, Luebeck, Germany; Emile A. Bacha, M.D., Children's Hospital Boston, Boston, Mass.; Paul Stelzer, M.D., Mt. Sinai Hospital, New York, N.Y.; Prof. John W. Brown, M.D., Indiana University, Indianapolis, Ind.; Hanneke Takkenberg, M.D., Ph.D., Erasmus University, Rotterdam, Netherlands; Michael F. Teodori, M.D., Phoenix Children's Hospital, Phoenix, Ariz.; Prof. Francisco da Costa, M.D., Santa Casa De Curitiba, Curitiba, Brazil; Prof. Neal Kon, M.D., Wake Forest University, Winston-Salem, NC.: Prof. Ross Ungerleider, M.D., Oregon Health & Science University, Portland, Ore.; and Giovanni Battista Luciani, M.D., University of Verona, Verona, Italy.

"The Ross Summit will create a unique atmosphere in which to engage in thought-provoking, interactive discussions about this ingenious surgical procedure with leading cardiovascular surgeons in the field," said Dr. Northrup. "The additional opportunity for hands-on valve implantation in a wet lab environment each day, led by Professors Yacoub and Sievers, offers an invaluable educational opportunity to these surgeons."

"The outstanding response we've received from the worldwide cardiovascular surgical community on this Summit is indicative of the professional interest in the Ross Procedure and in the new technologies and products related to it, such as the CryoValve SG," added Steven G. Anderson, chairman, president and CEO of CryoLife. "We look forward to hosting these surgeons and in playing a role in honing their technical skills, so that they can offer this surgical option to their patients."

About CryoLife, Inc.

Founded in 1984, CryoLife, Inc. is a leader in the processing and distribution of implantable living human tissues for use in cardiac and vascular surgeries throughout the U.S. and Canada. The Company recently received FDA clearance for the CryoValve(R) SG pulmonary human heart valve, processed using CryoLife's proprietary SynerGraft(R) Technology. The Company's BioGlue(R) Surgical Adhesive is FDA approved as an adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels. BioGlue is also CE marked in the European Community and approved in Canada and Australia for use in soft tissue repair. CryoLife distributes Hemostase MPH(R), a hemostatic agent, in much of the U.S. for use in cardiac and vascular surgery and in the United Kingdom, Germany, France and Canada for cardiac, vascular, and general surgery, subject to certain exclusions. The Company also distributes the CryoLife-O'Brien(R) Stentless Porcine Aortic Bioprosthesis, which is CE marked for distribution within the European Community.

For additional information about the company, visit CryoLife's Web site: http://www.cryolife.com

CryoLife Media Contacts:

D. Ashley Lee Katie Brazel

Executive Vice President, Chief Operating Officer Fleishman-Hillard

and Chief Financial Officer Phone: 404-739-0150

CryoLife, Inc.

Phone: 770-419-3355


'/>"/>
SOURCE CryoLife, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. CryoLife Expands Distribution of Hemostase MPH(R) to Canada through Sorin Group Canada, Inc.
2. CryoLife to Present at UBS Global Life Sciences Conference
3. CryoLife Expands Distribution of Hemostase MPH(R) to France through Laboratoire Gamida
4. CryoLife Announces Management Promotions
5. CryoLifes Earnings Per Share Increased 180 Percent to $0.14 in Second Quarter of 2008 from $0.05 in Second Quarter of 2007
6. CryoLife Announces Release Date and Teleconference Call Details for Second Quarter 2008 Financial Results
7. CryoLifes BioGlue(R) Surgical Adhesive Receives European Approval for use in Browlift Cosmetic and Reconstructive Plastic Surgery
8. CryoLife to Present at FBR Capital Markets Annual Spring Investor Conference
9. Harvey Morgan Joins CryoLife Board of Directors
10. CryoLife Conducts Surgeons Cardiac Allograft Symposium
11. CryoLife to Distribute FDA-approved Hemostatic Agent Under Private Label
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... Feb. 16, 2017 UCHealth ( Aurora, ... LungDirect for pulmonary nodule patient management. In addition to ... a spot on the lung, UCHealth looks to improve ... data entry. Stephanie Brown, RN , ... nodule patients with an Excel spreadsheet, which was extremely ...
(Date:2/16/2017)... HACKENSACK, N.J. , Feb. 16, 2017  Champions ... engaged in the development and sale of advanced technology ... of oncology drugs, today announced the addition of new ... These new models will expand Champions, product ... cancer, head and neck cancer, AML, and non-small cell ...
(Date:2/16/2017)... Feb. 16, 2017  Windtree Therapeutics, Inc. (Nasdaq: ... on developing aerosolized KL4 surfactant therapies for respiratory ... influenza study showed that aerosolized KL4 surfactant reduced ... well-established preclinical animal model. The Company believes that ... of evidence that supports the role of KL4 ...
(Date:2/16/2017)... PHOENIX and NEW YORK ... announced the near completion of their $7M Series B ... on top of the $3.5M led by Mesa Verde ... of 2016.  These resources will be directed towards further ... Test, PCDx, a comprehensive genomic profiling test and expanding ...
Breaking Biology Technology:
(Date:2/10/2017)... , Feb 10, 2017 Research ... report "Personalized Medicine - Scientific and Commercial Aspects" ... ... medicine. Diagnosis is integrated with therapy for selection of treatment ... early detection and prevention of disease in modern medicine. Biochip/microarray ...
(Date:2/8/2017)... Feb. 7, 2017  Aware, Inc. (NASDAQ: AWRE ... reported financial results for its quarter and year ended December ... of 2016 was $3.9 million compared to $6.9 million in ... quarter of 2016 was $0.6 million compared to $2.6 million ... fourth quarter of 2016 was $0.5 million, or $0.02 per ...
(Date:2/8/2017)... , Feb. 7, 2017 Report Highlights ... billion by 2021 from $8.3 billion in 2016 at ... 2016 to 2021. Report Includes - An overview ... global market trends, with data from 2015 and 2016, ... 2021. - Segmentation of the market on the basis ...
Breaking Biology News(10 mins):